<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CEP</journal-id>
<journal-id journal-id-type="hwp">spcep</journal-id>
<journal-title>Cephalalgia</journal-title>
<issn pub-type="ppub">0333-1024</issn>
<issn pub-type="epub">1468-2982</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0333102411435986</article-id>
<article-id pub-id-type="publisher-id">10.1177_0333102411435986</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Influence of memantine on nociceptive responses of the trigeminocervical complex after formalin injection</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Park</surname><given-names>Jeong Wook</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Suh</surname><given-names>Gyoung Im</given-names></name>
<xref ref-type="corresp" rid="corresp1-0333102411435986"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Shin</surname><given-names>Hae Eun</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Park</surname><given-names>Go Eun</given-names></name>
</contrib>
</contrib-group>
<aff id="aff1-0333102411435986">The Catholic University of Korea, South Korea</aff>
<author-notes>
<corresp id="corresp1-0333102411435986">Gyoung Im Suh, Department of Neurology, The Catholic University of Korea, College of Medicine, Uijeongbu St Mary's Hospital, 65-1 GeumoDong, Uijeongbu, Gyeongi Do. South Korea Email: <email>neurosuh@catholic.ac.kr</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>32</volume>
<issue>4</issue>
<fpage>308</fpage>
<lpage>316</lpage>
<history>
<date date-type="received"><day>24</day><month>8</month><year>2011</year></date>
<date date-type="rev-recd"><day>15</day><month>10</month><year>2011</year></date>
<date date-type="rev-recd"><day>5</day><month>12</month><year>2011</year></date>
<date date-type="accepted"><day>10</day><month>12</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© International Headache Society 2012 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">International Headache Society</copyright-holder>
</permissions>
<abstract>
<p><italic>Background:</italic> Glutamate receptors are implicated in central nervous system (CNS) pain pathways, including trigeminovascular activation, central sensitization, and cortical spreading depression.</p>
<p><italic>Methods:</italic> We investigated the influence of the <italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA) receptor antagonist memantine on pain pathways involving trigeminocervical complex (TCC) using a formalin injection model. In Sprague Dawley rats, formalin was delivered into the left periorbital area. Memantine (10 mg/kg) or vehicle was injected intraperitoneally 30 min before the formalin injection. The sensory threshold for mechanical stimulation, assessed by the von Frey monofilament threshold (VFMF), was measured 1 h and 2 h after formalin injection. Formalin-induced pain behavior was measured by monitoring the time spent rubbing the injected area during 60 min after formalin injection. The brainstem was then removed, and sections that spanned the TCC were cut, and stained with a Fos antibody.</p>
<p><italic>Results:</italic> Pretreatment with memantine significantly attenuated formalin-induced pain behavior (p &lt; 0.01) and the sensory threshold for VFMF (p &lt; 0.001). In the TCC, the increase in formalin-induced Fos immunoreactivity was significantly attenuated in the memantine group (p &lt; 0.01).</p>
<p><italic>Conclusion:</italic> The present study demonstrated that the NMDA receptor antagonist memantine inhibits the nociceptive process from trigemino-ophthalmic nerve endings to the TCC.</p>
</abstract>
<kwd-group>
<kwd>Trigeminal system</kwd>
<kwd>Fos</kwd>
<kwd>formalin</kwd>
<kwd>headache</kwd>
<kwd>trigeminocervical complex</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0333102411435986" sec-type="intro"><title>Introduction</title>
<p>Glutamate, a major excitatory neurotransmitter in the central nervous system, has a vital role in the mediation of synaptic transmissions (<xref ref-type="bibr" rid="bibr1-0333102411435986">1</xref>,<xref ref-type="bibr" rid="bibr2-0333102411435986">2</xref>). Electrophysiological and behavioral studies point to glutamate receptors as being essential for the spinal transmission of nociceptive information in physiological and pathological conditions (<xref ref-type="bibr" rid="bibr2-0333102411435986">2</xref>–<xref ref-type="bibr" rid="bibr5-0333102411435986">5</xref>). Administration of glutamate agonists can result in mechanical or thermal allodynia and hyperalgesia, known to be associated with the central sensitization of pain processes (<xref ref-type="bibr" rid="bibr6-0333102411435986">6</xref>). Glutamate antagonists have repeatedly been shown to inhibit pain-related responses as well as to enhance opioid-induced analgesia (<xref ref-type="bibr" rid="bibr7-0333102411435986">7</xref>–<xref ref-type="bibr" rid="bibr9-0333102411435986">9</xref>).</p>
<p>Pain relay structures, including the trigeminal ganglion, trigeminocervical complex (TCC), and thalamus, contain glutamate-positive neurons (<xref ref-type="bibr" rid="bibr10-0333102411435986">10</xref>,<xref ref-type="bibr" rid="bibr11-0333102411435986">11</xref>). Glutamate activates neurons in the trigeminal nucleus caudalis (TNC) by acting on ionotropic glutamate receptors and is involved in signaling from the spinothalamic tract (<xref ref-type="bibr" rid="bibr12-0333102411435986">12</xref>,<xref ref-type="bibr" rid="bibr13-0333102411435986">13</xref>). Many experimental studies with glutamate have reported significant effects in pain pathways, but clinical studies in humans have not been conducted because of concern about various side effects that may obscure the therapeutic potential (<xref ref-type="bibr" rid="bibr14-0333102411435986">14</xref>)</p>
<p><italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA) receptors, a type of ionotropic glutamate receptor, are tetrameric assemblies, including the NR1 and NR2 subunits, which provide potential sites of drug action within the NMDA protein complex (<xref ref-type="bibr" rid="bibr15-0333102411435986">15</xref>). Memantine has moderate affinity for the NR2B binding site (<xref ref-type="bibr" rid="bibr16-0333102411435986">16</xref>). In recent years, memantine has shown good tolerability; it has been used as a therapeutic agent for Alzheimer's disease.</p>
<p>The non-competitive NMDA receptor antagonist dizocilpine maleate inhibits neuronal firing in the trigeminocervical complex following electrical stimulation of the superior sagittal sinus (<xref ref-type="bibr" rid="bibr17-0333102411435986">17</xref>). There have been two studies evaluating the effect of memantine on pain perception; both evaluated only behavioral aspects of memantine using neuropathic and orofacial pain models (<xref ref-type="bibr" rid="bibr18-0333102411435986">18</xref>,<xref ref-type="bibr" rid="bibr19-0333102411435986">19</xref>). Clinically, memantine demonstrated significant effects in reducing headache frequency and disability when given as a preventative treatment for refractory migraine in an open-label study; side effects are uncommon and generally mild (<xref ref-type="bibr" rid="bibr20-0333102411435986">20</xref>). On the basis of these results, it is reasonable to hypothesize that memantine may have an inhibitory role in central pathway pain perception located in the TCC, but no study has yet directly demonstrated this relationship.</p>
<p>The current study used a formalin injection model, which has previously been shown to cause activation of a number of nuclei involved in the dorsal horn of the spinal cord in experimental animals (<xref ref-type="bibr" rid="bibr21-0333102411435986">21</xref>,<xref ref-type="bibr" rid="bibr22-0333102411435986">22</xref>). Subcutaneous formalin activates the Aδ and C nociceptors of sensory nerve endings and induces intense nociceptive input, with effects lasting 45–60 min, as assessed by behavioral observations (<xref ref-type="bibr" rid="bibr23-0333102411435986">23</xref>) and electrophysiological recordings (<xref ref-type="bibr" rid="bibr21-0333102411435986">21</xref>). This was shown to be a reliable method for assessing pain and has been used successfully in several recent studies. We used identification of the protein product of the immediate-early gene <italic>c-Fos</italic> as a marker of cellular activation; it is rapidly and transiently expressed in response to neuronal stimulation (<xref ref-type="bibr" rid="bibr24-0333102411435986">24</xref>). Previous studies have reported consistently that neurons within the TNC express Fos in response to irritant stimuli to pain-producing structures. We investigated the effect of memantine on trigeminocervical nociceptive responses after formalin injection to the trigemino–ophthalmic-innervated dermatome from the point of view of morphological and functional aspects.</p></sec>
<sec id="sec2-0333102411435986" sec-type="methods"><title>Methods</title>
<sec id="sec3-0333102411435986"><title>Animal preparation</title>
<p>Experiments were conducted after ethical review by the Institutional Animal Care and Use Committee at the Catholic University of Korea (approval number: UJA2011-02A). Male Sprague Dawley (SD) rats (200–250 g) were housed in standard plastic cages with sawdust bedding in a temperature-controlled room (23 ± 1°C) under a 12-h/12-h light/dark cycle. All procedures took place in the light phase, between 11:00 and 19:00 in a quiet room. Animals were randomized in a double-blind manner and were administered pretreatment with vehicle or memantine 30 min before the formalin injection.</p>
<p>Formalin was diluted in 0.9% saline to a concentration of 2.5%. A 50-μl bolus was then injected subcutaneously (s.c.) into the left side of the face over the upper eyelid, which corresponds to a trigemino–ophthalmic-innervated dermatome. To ensure calm, the injections were made under brief anesthesia, induced with enflurane through a nasal mask (Laboratoire Belamont). Anesthesia was discontinued when the first eye blink was observed. Under these conditions, the typical time for reawakening was less than 10 s. The animals were then placed in the 30 × 30 × 30-cm test box with three mirrored sides for a 60-min observation period. The rats did not have access to food or water during the test. Before formalin injection, the animals were usually placed in the same box for an acclimation period of 30 min. The observed responses involved two phases of rubbing. The first phase started 15–30 s after the test injection of formalin and lasted for 0–5 min. After a time of relative inactivity, a second phase of intense rubbing activity lasted 15–60 min after the injection. The recording time was divided into 12 blocks of 5 min, and a pain score was determined for each block by measuring the number of seconds that the animal spent rubbing the injected area with the ipsilateral forepaw. The data collected between 0 and 5 min post-formalin injection represented the early phase and the data collected between 15 and 60 min post-formalin injection represented the late phase. Behavioral analyses were performed by an investigator who was blinded to the animal's group assignment.</p>
<p>For the von Frey monofilament (VFMF) test, each rat was placed in an atraumatic plastic tube restraint, into which the animal entered uncoaxed. Animals were placed inside the testing apparatus for acclimation through the training period. Pressure thresholds were determined by applying the VFMF (Stoelting Co., Wood Dale, IL, USA) to the face over the periorbital region on both sides. The monofilaments were presented in a sequential ascending or descending order, to determine the threshold of response (<xref ref-type="bibr" rid="bibr25-0333102411435986">25</xref>,<xref ref-type="bibr" rid="bibr26-0333102411435986">26</xref>). A positive response to the VFMF was considered present when the rat showed recoil of the head away from the stimulus or vigorously stroked its face with the ipsilateral forepaw. The 66% probability thresholds of a positive response, defined as a positive response to two of three trials with the VFMF, were determined before and 1 h and 2 h after formalin injection.</p>
<p>The animals were then separated into three groups as follows:
<list id="list1-0333102411435986" list-type="order">
<list-item><p>Control group – animals received vehicle pretreatment (saline, 1 ml/kg intraperitoneally, i.p.) followed by vehicle injection in the left periorbital area (saline, 50 μl, s.c.; n = 6).</p></list-item>
<list-item><p>Formalin group – animals received vehicle pretreatment (saline, 1 ml/kg i.p.) followed by formalin injection in the left periorbital area (2.5% formalin, 50 μl, s.c.; n = 6).</p></list-item>
<list-item><p>Memantine group – animals received memantine pretreatment (10 mg/kg, i.p.) followed by formalin injection in the left periorbital area (2.5% formalin, 50 μl, s.c.; n = 6).</p></list-item>
</list></p></sec>
<sec id="sec4-0333102411435986"><title>Tissue preparation and immunohistochemistry</title>
<p>Following the experiment, the animals were killed by perfusion via the ascending aorta with 0.9% saline (50 ml), followed by 4% paraformaldehyde (50 ml) in 0.1 M phosphate-buffered saline (PBS, pH 7.4). The brain and spinal cord were removed and stored overnight in the same fixative and then placed in a cryoprotectant solution (20% sucrose, 30% ethylene glycol in 0.1 M PBS) for 48 h before sectioning. The brain and upper cervical spinal cord was sectioned serially on a freezing cryostat. Sections (30 µm) that spanned the trigeminocervical complex (trigeminal nucleus caudalis, cervical spinal cord, levels C1, C2, and C3) were collected in PBS.</p>
<p>Tissue sections were processed as free-floating sections. Sections were placed into 24-well plate, rinsed with 0.1 M PBS, and then incubated in 3% H<sub>2</sub>O<sub>2</sub> in 50% ethanol (Junsei Chemical, Tokyo, Japan) for 10 min. Sections were then rinsed in PBS and incubated in blocking solution (10% normal goat serum in 0.1 M PBS), followed by incubation overnight with the primary anti-Fos antibody, raised in rabbit (1:5000; pc38, Calbiochem, San Diego, CA, USA), diluted in 2% normal goat serum, 0.2% triton in PBS (Vector, Burlingame, CA, USA). The next morning, sections were again washed in PBS and then incubated in the secondary antibody (biotinylated anti-rabbit, raised in goat; Invitrogen, Camarillo, CA, USA) diluted at 1:500 in 2% normal goat serum in PBS for 20 min, followed by further washes in PBS. Sections were then incubated with an ExtrAvidin–peroxidase (Sigma, St Louis, MO, USA) for 2 h before a further series of washes in PBS. Finally, the sections were incubated with 3,3’-diaminobenzidine tetrahydrochloride dihydrate containing nickel (DAB; Vector) before being washed and mounted on slides, air-dried, dehydrated, and mounted in distyrene plasticizer xylene (DBX) medium under a cover slip (Thermo scientific, Cheshire, WA, UK).</p>
<p>Omission of the primary or secondary antibody abolished the immunocytochemical staining completely, indicating specificity. Fos immunoreactivity was distinguishable by cellular location: the nucleus was always labeled an intense dark brown-to-black, indicating the Fos protein.</p>
<p>All sections were examined under an Olympus Universal microscope equipped with a digital camera (Olympus, Shinjuku, Tokyo, Japan) by two investigators blinded to the animal groups being assessed. Methods for assessing Fos protein-stained nuclei have been described previously (<xref ref-type="bibr" rid="bibr27-0333102411435986">27</xref>). Briefly, for cells to be considered Fos-positive they had to be dark brown-to-black and round or ovoid, and they had to be visible under a light microscope at magnifications of 4×, 10×, and 20× objective plus a 10× eyepiece. Cytoarchitecturally identified regions of the superficial lamina of the TNC and of the upper cervical dorsal horn levels (C1–C3) of hemi-sections were examined for Fos-positive cells. The TNC was referenced to the obex according to coordinates provided by Paxinos and Franklin, and the cervical levels were determined based on the morphological appearance of the section under bright field illumination (<xref ref-type="bibr" rid="bibr28-0333102411435986">28</xref>). At each level, four randomly selected sections were assessed, and an average of all cells per hemi-section for each level was calculated to investigate the distribution pattern at each nucleus without prior knowledge of the treatment of each animal. All counts were made by the same experimenters to maintain consistency in the application of criteria used to select Fos-positive cells and to reduce the likelihood of subjective variability.</p></sec>
<sec id="sec5-0333102411435986"><title>Data analysis</title>
<p>Normally distributed data are reported as means (standard deviation), and data with unequal variances are reported as medians (interquartile range). The ANOVA test was used to assess differences between groups. Because quantitative measurements were made on an ordinal scale, statistical analyses were conducted using non-parametric statistics (<xref ref-type="bibr" rid="bibr29-0333102411435986">29</xref>). Comparisons between treatment groups were made using the Kruskal–Wallis analysis of variance, and the Mann–Whitney U test was used for differences between groups. For multiple comparisons, the Bonferroni correction was applied. For Fos counting, Cronbach’s coefficient α was used to assess intra- and intra-observer reproducibility for counts made by the two independent investigators. All observations from investigators had an α coefficient &gt;0.9 and thus values were pooled together. A probability of <italic>p &lt;</italic> 0.05 at the two-tailed level was considered to indicate statistical significance. Analyses were performed using the SPSS software (version 16.0; SPSS, Chicago, IL, USA).</p></sec></sec>
<sec id="sec6-0333102411435986" sec-type="results"><title>Results</title>
<sec id="sec7-0333102411435986"><title>Formalin-induced pain behavior</title>
<p>The control group was used to determine standard values for the early and late phases. Injection of formalin induced long-lasting face rubbing behavior that was characterized by two phases, as described previously (<xref ref-type="fig" rid="fig1-0333102411435986">Figure 1</xref>). Memantine pretreatment attenuated formalin-induced pain behavior, though this was significant only in the late phase (<italic>p</italic> &lt; 0.01; <xref ref-type="fig" rid="fig2-0333102411435986">Figure 2</xref>).
<fig id="fig1-0333102411435986" position="float"><label>Figure 1.</label><caption><p>Time course of face rubbing activity observed after formalin injection in each group. The mean number of seconds that rats spent rubbing is plotted for each 5-min block over the 60-min post-injection observation period.</p></caption><graphic xlink:href="10.1177_0333102411435986-fig1.tif"/></fig>
<fig id="fig2-0333102411435986" position="float"><label>Figure 2.</label><caption><p>Comparisons of the early and late phases of formalin-induced face rubbing activity in each group. *p &lt; 0.05, compared with the control group. **p &lt; 0.05, compared with the formalin group.</p></caption><graphic xlink:href="10.1177_0333102411435986-fig2.tif"/></fig></p></sec>
<sec id="sec8-0333102411435986"><title>Von Frey filament test</title>
<p>The VFMF thresholds are presented as proportional values to those of the contralateral site of the injected area. In the control group, the periorbital VFMF threshold ipsilateral to vehicle injection was not significantly different from the threshold contralateral to vehicle injection (df(2) = 710.4; p = 0.13).</p>
<p>The periorbital VFMF thresholds ipsilateral to the formalin-injected site decreased significantly 1 h and 2 h after formalin injection (df(2) = 6598.1; <italic>p</italic> &lt; 0.01). In the memantine group, the periorbital VFMF thresholds were unchanged after formalin injection (df(2) = 529.2; p = 0.45; <xref ref-type="fig" rid="fig3-0333102411435986">Figure 3</xref>).
<fig id="fig3-0333102411435986" position="float"><label>Figure 3.</label><caption><p>Comparison of von Frey response thresholds at pretreatment and at 1 h and 2 h after formalin injection in each experimental group. *p &lt; 0.05, compared with baseline.</p></caption><graphic xlink:href="10.1177_0333102411435986-fig3.tif"/></fig></p></sec>
<sec id="sec9-0333102411435986"><title>FOS immunoreactivity</title>
<p>In both groups, Fos-positive neurons were located primarily within the superficial laminae of the TNC and laminae I and II of the C1–C3 levels.</p>
<p>There was a significant difference in the number of Fos-positive cells across the three groups (H(2) = 9.17; p = 0.01). The number of Fos-positive cells increased significantly following formalin injection versus the control group (p = 0.01). Memantine pretreatment significantly decreased the number of Fos-positive cells as compared with the formalin group (p = 0.009), and the number of positive cells was similar to that of the control group (p = 0.59).</p>
<p>Data on the Fos-positive cells in each level of the TCC are presented in <xref ref-type="table" rid="table1-0333102411435986">Table 1</xref>, and the distribution of Fos-positive cells in each experimental group is shown in <xref ref-type="fig" rid="fig4-0333102411435986">Figure 4</xref>. The integrated counts of TCC for each group are presented in <xref ref-type="fig" rid="fig5-0333102411435986">Figure 5</xref>.
<fig id="fig4-0333102411435986" position="float"><label>Figure 4.</label><caption><p>Representative microphotographs of dorsal horn sections at the C2 level from each experimental group immunostained for Fos following formalin injection. Scale bars = 200 µm for all images.</p></caption><graphic xlink:href="10.1177_0333102411435986-fig4.tif"/></fig>
<fig id="fig5-0333102411435986" position="float"><label>Figure 5.</label><caption><p>Comparisons of Fos-positive cells per animal in the trigeminocervical complex (TCC) in each treatment group. *p &lt; 0.05, compared with the control. **p &lt; 0.05, compared with the formalin group.</p></caption><graphic xlink:href="10.1177_0333102411435986-fig5.tif"/></fig>
<table-wrap id="table1-0333102411435986" position="float"><label>Table 1.</label><caption><p>The number of Fos-positive cells (25th – 75th percentile) per hemi-section per animal in each trigeminocervical region in each group</p></caption>
<graphic alternate-form-of="table1-0333102411435986" xlink:href="10.1177_0333102411435986-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>Control</th>
<th>Formalin</th>
<th>Memantine</th></tr></thead>
<tbody align="left">
<tr>
<td>TNC</td>
<td>48.8 (24.9–73.9)</td>
<td>61.5 (54.8–74.2)</td>
<td>56.0 (40.3–64.3)</td></tr>
<tr>
<td>C1</td>
<td>31.4 (17.4–48.9)</td>
<td>101.0 (92.4–104.2)</td>
<td>23.1 (17.4–66.7)</td></tr>
<tr>
<td>C2</td>
<td>49.6 (33.9–54.5)</td>
<td>131.5 (105.1–136.6)</td>
<td>41.5 (29.1–73.8)</td></tr>
<tr>
<td>C3</td>
<td>28.2 (13.8–31.9)</td>
<td>118.8 (86.9–134.7)</td>
<td>38.5 (29.1–75.6)</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0333102411435986"><p>TNC, trigeminal nucleus caudalis; C1–C3; cervical levels of the spinal cord.</p></fn></table-wrap-foot>
</table-wrap></p></sec></sec>
<sec id="sec10-0333102411435986" sec-type="discussion"><title>Discussion</title>
<p>In contrast to most previous studies that injected formalin into the perioral area to induce orofacial pain, we used the periorbital area, which is a trigemino–ophthalmic-branch-innervated dermatome, to focus on headache pathophysiology. Unmyelinated C-fibers from the ophthalmic division of the trigeminal nerve are known to be important in the development of headaches (<xref ref-type="bibr" rid="bibr30-0333102411435986">30</xref>,<xref ref-type="bibr" rid="bibr31-0333102411435986">31</xref>). Electrophysiological studies showed that activated neurons of the trigeminocervical complex after stimulation of the superior sagittal sinus or the middle meningeal artery exactly corresponded to those of the TCC after cutaneous sensory stimulation to the periorbital area (<xref ref-type="bibr" rid="bibr32-0333102411435986">32</xref>–<xref ref-type="bibr" rid="bibr34-0333102411435986">34</xref>). In an experimental approach for evaluating migraine, the sensory threshold for pain/temperature at the ophthalmic dermatome was altered to assess trigeminovascular system sensitization (<xref ref-type="bibr" rid="bibr35-0333102411435986">35</xref>,<xref ref-type="bibr" rid="bibr36-0333102411435986">36</xref>). About two-thirds of migraine patients complain of hyperalgesia or allodynia at ophthalmic dermatomes, including in the forehead, which reflect central sensitization at the TCC (<xref ref-type="bibr" rid="bibr37-0333102411435986">37</xref>). The presence of allodynia could be an important consideration for therapeutic limitations in migraine treatments (<xref ref-type="bibr" rid="bibr37-0333102411435986">37</xref>,<xref ref-type="bibr" rid="bibr38-0333102411435986">38</xref>). The distribution of Fos-positive neurons in the present study corresponded to the trigeminocervical complex proper, that is, the lower portion of TNC and C1-C3 cervical dorsal horn, and this was identical to the region that responds to stimulation of the perivascular nerve endings of the trigeminal nerve around the superior sagittal sinus or middle meningeal artery (<xref ref-type="bibr" rid="bibr32-0333102411435986">32</xref>,<xref ref-type="bibr" rid="bibr39-0333102411435986">39</xref>,<xref ref-type="bibr" rid="bibr40-0333102411435986">40</xref>). The biphasic behavioral response to formalin injection is also comparable to those observed in orofacial formalin tests (<xref ref-type="bibr" rid="bibr18-0333102411435986">18</xref>,<xref ref-type="bibr" rid="bibr41-0333102411435986">41</xref>). Thus, the periorbital formalin injection model could be a useful tool for further experimental approaches to the pathogenesis of headaches.</p>
<p>We have demonstrated that the NMDA receptor antagonist memantine attenuated formalin-induced pain behavior, and the late phase seemed to be inhibited to a significant extent. After formalin injection, chemoreceptors are activated on the peripheral terminals of primary afferents to produce brief, phasic pain behavior in the early phase. During the late phase, which is the result of central sensitization of second-order neurons (<xref ref-type="bibr" rid="bibr19-0333102411435986">19</xref>,<xref ref-type="bibr" rid="bibr42-0333102411435986">42</xref>), glutamate is released, producing lasting, tonic nociceptive behavior (<xref ref-type="bibr" rid="bibr43-0333102411435986">43</xref>,<xref ref-type="bibr" rid="bibr44-0333102411435986">44</xref>). Interestingly, the temporal profiles of these biphasic responses approximately parallel those of peripheral nociceptors (<xref ref-type="bibr" rid="bibr45-0333102411435986">45</xref>) and convergent neurons (<xref ref-type="bibr" rid="bibr3-0333102411435986">3</xref>,<xref ref-type="bibr" rid="bibr46-0333102411435986">46</xref>,<xref ref-type="bibr" rid="bibr47-0333102411435986">47</xref>). Previous experimental approaches showed that NMDA receptors are involved in pain-related phenomena (<xref ref-type="bibr" rid="bibr18-0333102411435986">18</xref>,<xref ref-type="bibr" rid="bibr48-0333102411435986">48</xref>). Pain sensitization of dorsal horn neurons after peripheral inflammation-induced neuropathic pain is dependent on NMDA activity (<xref ref-type="bibr" rid="bibr49-0333102411435986">49</xref>). Nociceptive behaviors are selectively enhanced by pretreatment with a NMDA agonist, but not with a 2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid (AMPA) or a metabotropic receptor agonist (<xref ref-type="bibr" rid="bibr49-0333102411435986">49</xref>). Development and expression of responses during the late phase are believed to be NMDA receptor-dependent (<xref ref-type="bibr" rid="bibr3-0333102411435986">3</xref>), and NMDA agonists increase the nociceptive response only in the late phase following subcutaneous formalin injection into the hind paw (<xref ref-type="bibr" rid="bibr49-0333102411435986">49</xref>). Memantine reduces nociceptive behavioral responses in chronic pain and neuropathic pain models, and this has been observed within therapeutically relevant dose ranges (<xref ref-type="bibr" rid="bibr16-0333102411435986">16</xref>,<xref ref-type="bibr" rid="bibr19-0333102411435986">19</xref>,<xref ref-type="bibr" rid="bibr25-0333102411435986">25</xref>,<xref ref-type="bibr" rid="bibr50-0333102411435986">50</xref>). In a study by Eisenberg et al., memantine blocked the formalin-induced late phase at dose levels substantially lower than those required for suppression of the early phase (<xref ref-type="bibr" rid="bibr19-0333102411435986">19</xref>).</p>
<p>The results of the present study, which showed preferential inhibition of late phase formalin-induced pain behaviors by memantine, suggest that this drug might have useful effects for central sensitization of second order neurons in the pain transmission pathway rather than those involved in peripheral acceptance of pain signal inputs.</p>
<p>Because many NMDA receptor antagonists produce behavioral changes, such as hyperactivity and motor dysfunction, it is important to consider the possibility that the reduction in pain behavior may be due to a non-specific behavioral effect of memantine (<xref ref-type="bibr" rid="bibr51-0333102411435986">51</xref>). Although the present study did not involve quantitative assessment of motor impairment, the exploratory and freezing behaviors displayed with memantine treatment were comparable to those in the vehicle-treated control group. Moreover, it has been consistently reported that the dose used in the present study (10 mg/kg) does not cause motor impairment (<xref ref-type="bibr" rid="bibr16-0333102411435986">16</xref>,<xref ref-type="bibr" rid="bibr25-0333102411435986">25</xref>,<xref ref-type="bibr" rid="bibr48-0333102411435986">48</xref>). Indeed, memantine did not cause motor impairment at doses up to 20 mg/kg (<xref ref-type="bibr" rid="bibr48-0333102411435986">48</xref>).</p>
<p>The present study showed that pretreatment with memantine attenuated formalin injection-induced c-Fos immunoreactivity in the TCC. Glutamate receptors are present in the superficial layer of the dorsal horn, especially in the C-fiber process and their central terminal (<xref ref-type="bibr" rid="bibr10-0333102411435986">10</xref>) and lead to neuronal plasticity in the spinal cord, producing central pain sensitization (<xref ref-type="bibr" rid="bibr52-0333102411435986">52</xref>,<xref ref-type="bibr" rid="bibr53-0333102411435986">53</xref>). Glutamate antagonists reduce excitation in the spinal cord by primary afferent stimulation (<xref ref-type="bibr" rid="bibr53-0333102411435986">53</xref>,<xref ref-type="bibr" rid="bibr54-0333102411435986">54</xref>) and block wide dynamic neuronal firing in the spinal cord (<xref ref-type="bibr" rid="bibr53-0333102411435986">53</xref>,<xref ref-type="bibr" rid="bibr55-0333102411435986">55</xref>).</p>
<p>The NR2B subunits of NMDA receptors are localized predominantly in the superficial layer of the dorsal horn (<xref ref-type="bibr" rid="bibr56-0333102411435986">56</xref>,<xref ref-type="bibr" rid="bibr57-0333102411435986">57</xref>). These subunits are involved in central sensitization in the spinal cord (<xref ref-type="bibr" rid="bibr58-0333102411435986">58</xref>). Several NR2B antagonists are currently being studied in different experimental models of nociception (<xref ref-type="bibr" rid="bibr59-0333102411435986">59</xref>,<xref ref-type="bibr" rid="bibr60-0333102411435986">60</xref>). Furthermore, a recent study has shown that selective knockdown of NR2B in the dorsal horn using short interfering RNA can suppress formalin-induced nociceptive behavior (<xref ref-type="bibr" rid="bibr61-0333102411435986">61</xref>). The restricted distribution of NR2B receptors makes them promising candidates as targets for side-effect-free analgesics (<xref ref-type="bibr" rid="bibr62-0333102411435986">62</xref>). Memantine has NMDA (NR2B) receptor-channel binding affinity (<xref ref-type="bibr" rid="bibr16-0333102411435986">16</xref>). Memantine preferentially blocks excessive NMDA receptor activity without disrupting normal activity because it enters the receptor-associated ion channel preferentially when it is excessively open and, most importantly, its off rate is relatively fast, so it does not accumulate substantially in the channel to interfere with subsequent normal synaptic transmission (<xref ref-type="bibr" rid="bibr63-0333102411435986">63</xref>).</p></sec>
<sec id="sec11-0333102411435986" sec-type="conclusions"><title>Conclusion</title>
<p>After a formalin injection into a trigemino–ophthalmic-branch-innervated dermatome, the anti-nociceptive effect of memantine on pain behavior and Fos expression in the TCC had established. Similar to topiramate and divalproex sodium, which have negative modulatory effects on glutamate receptors, memantine could be a possible candidate for use in the preventative treatment of headaches (<xref ref-type="bibr" rid="bibr64-0333102411435986">64</xref>).</p></sec>
</body>
<back>
<sec id="sec12-0333102411435986"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for profit sectors.</p></sec>
<sec id="sec13-0333102411435986"><title>Declaration of conflicting interests</title>
<p>The authors declare that there is no conflict of interest.</p></sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0333102411435986"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kew</surname><given-names>JN</given-names></name><name><surname>Kemp</surname><given-names>JA</given-names></name></person-group>. <article-title>Ionotropic and metabotropic glutamate receptor structure and pharmacology</article-title>. <source>Psychopharmacology (Berl)</source> <year>2005</year>; <volume>179</volume>: <fpage>4</fpage>–<lpage>29</lpage>.</citation></ref>
<ref id="bibr2-0333102411435986"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andreou</surname><given-names>AP</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group>. <article-title>Therapeutic potential of novel glutamate receptor antagonists in migraine</article-title>. <source>Expert Opin Investig Drugs</source> <year>2009</year>; <volume>18</volume>: <fpage>789</fpage>–<lpage>803</lpage>.</citation></ref>
<ref id="bibr3-0333102411435986"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haley</surname><given-names>JE</given-names></name><name><surname>Sullivan</surname><given-names>AF</given-names></name><name><surname>Dickenson</surname><given-names>AH</given-names></name></person-group>. <article-title>Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat</article-title>. <source>Brain Res</source> <year>1990</year>; <volume>518</volume>: <fpage>218</fpage>–<lpage>226</lpage>.</citation></ref>
<ref id="bibr4-0333102411435986"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hudspith</surname><given-names>MJ</given-names></name><name><surname>Harrisson</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>G</given-names></name><name><surname>Bountra</surname><given-names>C</given-names></name><name><surname>Elliot</surname><given-names>PJ</given-names></name><name><surname>Birch</surname><given-names>PJ</given-names></name><etal/></person-group>. <article-title>Effect of post-injury NMDA antagonist treatment on long-term Fos expression and hyperalgesia in a model of chronic neuropathic pain</article-title>. <source>Brain Res</source> <year>1999</year>; <volume>822</volume>: <fpage>220</fpage>–<lpage>227</lpage>.</citation></ref>
<ref id="bibr5-0333102411435986"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Munglani</surname><given-names>R</given-names></name><name><surname>Hudspith</surname><given-names>MJ</given-names></name><name><surname>Fleming</surname><given-names>B</given-names></name><name><surname>Harrisson</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>G</given-names></name><name><surname>Bountra</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Effect of pre-emptive NMDA antagonist treatment on long-term Fos expression and hyperalgesia in a model of chronic neuropathic pain</article-title>. <source>Brain Res</source> <year>1999</year>; <volume>822</volume>: <fpage>210</fpage>–<lpage>219</lpage>.</citation></ref>
<ref id="bibr6-0333102411435986"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Bonasera</surname><given-names>L</given-names></name><name><surname>Carlton</surname><given-names>SM</given-names></name></person-group>. <article-title>Peripheral administration of NMDA, AMPA or KA results in pain behaviors in rats</article-title>. <source>Neuroreport</source> <year>1996</year>; <volume>7</volume>: <fpage>895</fpage>–<lpage>900</lpage>.</citation></ref>
<ref id="bibr7-0333102411435986"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>RM</given-names></name><name><surname>Dykstra</surname><given-names>LA</given-names></name></person-group>. <article-title>N-methyl-D-aspartate receptor antagonists potentiate the antinociceptive effects of morphine in squirrel monkeys</article-title>. <source>J Pharmacol Exp Ther</source> <year>2001</year>; <volume>298</volume>: <fpage>288</fpage>–<lpage>297</lpage>.</citation></ref>
<ref id="bibr8-0333102411435986"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bespalov</surname><given-names>A</given-names></name><name><surname>Kudryashova</surname><given-names>M</given-names></name><name><surname>Zvartau</surname><given-names>E</given-names></name></person-group>. <article-title>Prolongation of morphine analgesia by competitive NMDA receptor antagonist D-CPPene (SDZ EAA 494) in rats</article-title>. <source>Eur J Pharmacol</source> <year>1998</year>; <volume>351</volume>: <fpage>299</fpage>–<lpage>305</lpage>.</citation></ref>
<ref id="bibr9-0333102411435986"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grass</surname><given-names>S</given-names></name><name><surname>Hoffmann</surname><given-names>O</given-names></name><name><surname>Xu</surname><given-names>XJ</given-names></name><name><surname>Wiesenfeld-Hallin</surname><given-names>Z</given-names></name></person-group>. <article-title>N-methyl-D-aspartate receptor antagonists potentiate morphine's antinociceptive effect in the rat</article-title>. <source>Acta Physiol Scand</source> <year>1996</year>; <volume>158</volume>: <fpage>269</fpage>–<lpage>273</lpage>.</citation></ref>
<ref id="bibr10-0333102411435986"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greenamyre</surname><given-names>JT</given-names></name><name><surname>Young</surname><given-names>AB</given-names></name><name><surname>Penney</surname><given-names>JB</given-names></name></person-group>. <article-title>Quantitative autoradiographic distribution of L-[3H]glutamate-binding sites in rat central nervous system</article-title>. <source>J Neurosci</source> <year>1984</year>; <volume>4</volume>: <fpage>2133</fpage>–<lpage>2144</lpage>.</citation></ref>
<ref id="bibr11-0333102411435986"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kai-Kai</surname><given-names>MA</given-names></name><name><surname>Howe</surname><given-names>R</given-names></name></person-group>. <article-title>Glutamate-immunoreactivity in the trigeminal and dorsal root ganglia, and intraspinal neurons and fibres in the dorsal horn of the rat</article-title>. <source>Histochem J</source> <year>1991</year>; <volume>23</volume>: <fpage>171</fpage>–<lpage>179</lpage>.</citation></ref>
<ref id="bibr12-0333102411435986"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tallaksen-Greene</surname><given-names>SJ</given-names></name><name><surname>Young</surname><given-names>AB</given-names></name><name><surname>Penney</surname><given-names>JB</given-names></name><name><surname>Beitz</surname><given-names>AJ</given-names></name></person-group>. <article-title>Excitatory amino acid binding sites in the trigeminal principal sensory and spinal trigeminal nuclei of the rat</article-title>. <source>Neurosci Lett</source> <year>1992</year>; <volume>141</volume>: <fpage>79</fpage>–<lpage>83</lpage>.</citation></ref>
<ref id="bibr13-0333102411435986"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Broman</surname><given-names>J</given-names></name><name><surname>Ottersen</surname><given-names>OP</given-names></name></person-group>. <article-title>Cervicothalamic tract terminals are enriched in glutamate-like immunoreactivity: an electron microscopic double-labeling study in the cat</article-title>. <source>J Neurosci</source> <year>1992</year>; <volume>12</volume>: <fpage>204</fpage>–<lpage>221</lpage>.</citation></ref>
<ref id="bibr14-0333102411435986"><label>14.</label><citation citation-type="book"><person-group person-group-type="editor"><name><surname>Balster</surname><given-names>RL</given-names></name><name><surname>Willetts</surname><given-names>J</given-names></name></person-group>. <source>Phencyclidine: a drug of abuse and a tool for neuroscience research</source>. <publisher-loc>Berlin</publisher-loc>: <publisher-name>Springer-Verlag</publisher-name>, <year>1996</year>.</citation></ref>
<ref id="bibr15-0333102411435986"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mothet</surname><given-names>JP</given-names></name><name><surname>Parent</surname><given-names>AT</given-names></name><name><surname>Wolosker</surname><given-names>H</given-names></name><name><surname>Brady</surname><given-names>RO</given-names><suffix>Jr</suffix></name><name><surname>Linden</surname><given-names>DJ</given-names></name><name><surname>Ferris</surname><given-names>CD</given-names></name><etal/></person-group>. <article-title>D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2000</year>; <volume>97</volume>: <fpage>4926</fpage>–<lpage>4931</lpage>.</citation></ref>
<ref id="bibr16-0333102411435986"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Medvedev</surname><given-names>IO</given-names></name><name><surname>Malyshkin</surname><given-names>AA</given-names></name><name><surname>Belozertseva</surname><given-names>IV</given-names></name><name><surname>Sukhotina</surname><given-names>IA</given-names></name><name><surname>Sevostianova</surname><given-names>NY</given-names></name><name><surname>Aliev</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain</article-title>. <source>Neuropharmacology</source> <year>2004</year>; <volume>47</volume>: <fpage>175</fpage>–<lpage>183</lpage>.</citation></ref>
<ref id="bibr17-0333102411435986"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Storer</surname><given-names>RJ</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group>. <article-title>Trigeminovascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors</article-title>. <source>Neuroscience</source> <year>1999</year>; <volume>90</volume>: <fpage>1371</fpage>–<lpage>1376</lpage>.</citation></ref>
<ref id="bibr18-0333102411435986"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eisenberg</surname><given-names>E</given-names></name><name><surname>LaCross</surname><given-names>S</given-names></name><name><surname>Strassman</surname><given-names>AM</given-names></name></person-group>. <article-title>The clinically tested N-methyl-D-aspartate receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy</article-title>. <source>Neurosci Lett</source> <year>1995</year>; <volume>187</volume>: <fpage>17</fpage>–<lpage>20</lpage>.</citation></ref>
<ref id="bibr19-0333102411435986"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eisenberg</surname><given-names>E</given-names></name><name><surname>Vos</surname><given-names>BP</given-names></name><name><surname>Strassman</surname><given-names>AM</given-names></name></person-group>. <article-title>The NMDA antagonist memantine blocks pain behavior in a rat model of formalin-induced facial pain</article-title>. <source>Pain</source> <year>1993</year>; <volume>54</volume>: <fpage>301</fpage>–<lpage>307</lpage>.</citation></ref>
<ref id="bibr20-0333102411435986"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bigal</surname><given-names>M</given-names></name><name><surname>Rapoport</surname><given-names>A</given-names></name><name><surname>Sheftell</surname><given-names>F</given-names></name><name><surname>Tepper</surname><given-names>D</given-names></name><name><surname>Tepper</surname><given-names>S</given-names></name></person-group>. <article-title>Memantine in the preventive treatment of refractory migraine</article-title>. <source>Headache</source> <year>2008</year>; <volume>48</volume>: <fpage>1337</fpage>–<lpage>1342</lpage>.</citation></ref>
<ref id="bibr21-0333102411435986"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dickenson</surname><given-names>AH</given-names></name><name><surname>Sullivan</surname><given-names>AF</given-names></name></person-group>. <article-title>Subcutaneous formalin-induced activity of dorsal horn neurones in the rat: differential response to an intrathecal opiate administered pre or post formalin</article-title>. <source>Pain</source> <year>1987</year>; <volume>30</volume>: <fpage>349</fpage>–<lpage>360</lpage>.</citation></ref>
<ref id="bibr22-0333102411435986"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duale</surname><given-names>C</given-names></name><name><surname>Luccarini</surname><given-names>P</given-names></name><name><surname>Cadet</surname><given-names>R</given-names></name><name><surname>Woda</surname><given-names>A</given-names></name></person-group>. <article-title>Effects of morphine microinjections into the trigeminal sensory complex on the formalin test in the rat</article-title>. <source>Exp Neurol</source> <year>1996</year>; <volume>142</volume>: <fpage>331</fpage>–<lpage>339</lpage>.</citation></ref>
<ref id="bibr23-0333102411435986"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raboisson</surname><given-names>P</given-names></name><name><surname>Dallel</surname><given-names>R</given-names></name></person-group>. <article-title>The orofacial formalin test</article-title>. <source>Neurosci Biobehav Rev</source> <year>2004</year>; <volume>28</volume>: <fpage>219</fpage>–<lpage>226</lpage>.</citation></ref>
<ref id="bibr24-0333102411435986"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>JI</given-names></name><name><surname>Curran</surname><given-names>T</given-names></name></person-group>. <article-title>Stimulus-transcription coupling in neurons: role of cellular immediate-early genes</article-title>. <source>Trends Neurosci</source> <year>1989</year>; <volume>12</volume>: <fpage>459</fpage>–<lpage>462</lpage>.</citation></ref>
<ref id="bibr25-0333102411435986"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaplan</surname><given-names>SR</given-names></name><name><surname>Bach</surname><given-names>FW</given-names></name><name><surname>Pogrel</surname><given-names>JW</given-names></name><name><surname>Chung</surname><given-names>JM</given-names></name><name><surname>Yaksh</surname><given-names>TL</given-names></name></person-group>. <article-title>Quantitative assessment of tactile allodynia in the rat paw</article-title>. <source>J Neurosci Methods</source> <year>1994</year>; <volume>53</volume>: <fpage>55</fpage>–<lpage>63</lpage>.</citation></ref>
<ref id="bibr26-0333102411435986"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vos</surname><given-names>BP</given-names></name><name><surname>Strassman</surname><given-names>AM</given-names></name><name><surname>Maciewicz</surname><given-names>RJ</given-names></name></person-group>. <article-title>Behavioral evidence of trigeminal neuropathic pain following chronic constriction injury to the rat's infraorbital nerve</article-title>. <source>J Neurosci</source> <year>1994</year>; <volume>14</volume>: <fpage>2708</fpage>–<lpage>2723</lpage>.</citation></ref>
<ref id="bibr27-0333102411435986"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benjamin</surname><given-names>L</given-names></name><name><surname>Levy</surname><given-names>MJ</given-names></name><name><surname>Lasalandra</surname><given-names>MP</given-names></name><name><surname>Knight</surname><given-names>YE</given-names></name><name><surname>Akerman</surname><given-names>S</given-names></name><name><surname>Classey</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>Hypothalamic activation after stimulation of the superior sagittal sinus in the cat: a Fos study</article-title>. <source>Neurobiol Dis</source> <year>2004</year>; <volume>16</volume>: <fpage>500</fpage>–<lpage>505</lpage>.</citation></ref>
<ref id="bibr28-0333102411435986"><label>28.</label><citation citation-type="book"><person-group person-group-type="editor"><name><surname>Paxinos</surname><given-names>G</given-names></name><name><surname>Franklin</surname><given-names>KBJ</given-names></name></person-group>. <source>The rat brain in stereotaxic coordinates</source>, <edition>2nd edn</edition>. <publisher-loc>London</publisher-loc>: <publisher-name>Academic Press</publisher-name>, <year>2003</year>.</citation></ref>
<ref id="bibr29-0333102411435986"><label>29.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>S</given-names></name></person-group>. <source><italic>Non-parametric Statistics for the Behavioural Sciences</italic></source>. <publisher-loc>Kogakusha, Tokyo</publisher-loc>: <publisher-name>McGraw-Hill</publisher-name>, <year>1956</year>.</citation></ref>
<ref id="bibr30-0333102411435986"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitsikostas</surname><given-names>DD</given-names></name><name><surname>Sanchez del Rio</surname><given-names>M</given-names></name></person-group>. <article-title>Receptor systems mediating c-fos expression within trigeminal nucleus caudalis in animal models of migraine</article-title>. <source>Brain Res Brain Res Rev</source> <year>2001</year>; <volume>35</volume>: <fpage>20</fpage>–<lpage>35</lpage>.</citation></ref>
<ref id="bibr31-0333102411435986"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Potrebic</surname><given-names>S</given-names></name><name><surname>Ahn</surname><given-names>AH</given-names></name><name><surname>Skinner</surname><given-names>K</given-names></name><name><surname>Fields</surname><given-names>HL</given-names></name><name><surname>Basbaum</surname><given-names>AI</given-names></name></person-group>. <article-title>Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective antimigraine action of triptans</article-title>. <source>J Neurosci</source> <year>2003</year>; <volume>23</volume>: <fpage>10988</fpage>–<lpage>10997</lpage>.</citation></ref>
<ref id="bibr32-0333102411435986"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoskin</surname><given-names>KL</given-names></name><name><surname>Bulmer</surname><given-names>DC</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group>. <article-title>Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME</article-title>. <source>Neurosci Lett</source> <year>1999</year>; <volume>266</volume>: <fpage>173</fpage>–<lpage>176</lpage>.</citation></ref>
<ref id="bibr33-0333102411435986"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Classey</surname><given-names>JD</given-names></name><name><surname>Knight</surname><given-names>YE</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group>. <article-title>The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity within the trigeminocervical complex following superior sagittal sinus stimulation in the cat</article-title>. <source>Brain Res</source> <year>2001</year>; <volume>907</volume>: <fpage>117</fpage>–<lpage>124</lpage>.</citation></ref>
<ref id="bibr34-0333102411435986"><label>34.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bergerot</surname><given-names>A</given-names></name><name><surname>Storer</surname><given-names>RJ</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group>. <article-title>Dopamine inhibits trigeminovascular transmission in the rat</article-title>. <source>Ann Neurol</source> <year>2007</year>; <volume>61</volume>: <fpage>251</fpage>–<lpage>262</lpage>.</citation></ref>
<ref id="bibr35-0333102411435986"><label>35.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>R</given-names></name><name><surname>Cutrer</surname><given-names>MF</given-names></name><name><surname>Yarnitsky</surname><given-names>D</given-names></name></person-group>. <article-title>The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine</article-title>. <source>Brain</source> <year>2000</year>; <volume>123</volume>: <fpage>1703</fpage>–<lpage>1709</lpage>.</citation></ref>
<ref id="bibr36-0333102411435986"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>R</given-names></name><name><surname>Yamamura</surname><given-names>H</given-names></name><name><surname>Malick</surname><given-names>A</given-names></name><name><surname>Strassman</surname><given-names>AM</given-names></name></person-group>. <article-title>Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons</article-title>. <source>J Neurophysiol</source> <year>1998</year>; <volume>79</volume>: <fpage>964</fpage>–<lpage>982</lpage>.</citation></ref>
<ref id="bibr37-0333102411435986"><label>37.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group>. <article-title>Migraine, allodynia, sensitisation and all of that</article-title>. <source>Eur Neurol</source> <year>2005</year>; <volume>53</volume>(<issue>Suppl 1</issue>): <fpage>10</fpage>–<lpage>16</lpage>.</citation></ref>
<ref id="bibr38-0333102411435986"><label>38.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group>. <article-title>The ‘Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine</article-title>. <source>Cephalalgia</source> <year>2008</year>; <volume>28</volume>(<issue>Suppl 2</issue>): <fpage>36</fpage>–<lpage>41</lpage>.</citation></ref>
<ref id="bibr39-0333102411435986"><label>39.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoskin</surname><given-names>KL</given-names></name><name><surname>Zagami</surname><given-names>AS</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group>. <article-title>Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat</article-title>. <source>J Anat</source> <year>1999</year>; <volume>194</volume>: <fpage>579</fpage>–<lpage>588</lpage>.</citation></ref>
<ref id="bibr40-0333102411435986"><label>40.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goadsby</surname><given-names>PJ</given-names></name><name><surname>Hoskin</surname><given-names>KL</given-names></name><name><surname>Knight</surname><given-names>YE</given-names></name></person-group>. <article-title>Substance P blockade with the potent and centrally acting antagonist GR205171 does not effect central trigeminal activity with superior sagittal sinus stimulation</article-title>. <source>Neuroscience</source> <year>1998</year>; <volume>86</volume>: <fpage>337</fpage>–<lpage>343</lpage>.</citation></ref>
<ref id="bibr41-0333102411435986"><label>41.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dubuisson</surname><given-names>D</given-names></name><name><surname>Dennis</surname><given-names>SG</given-names></name></person-group>. <article-title>The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats</article-title>. <source>Pain</source> <year>1977</year>; <volume>4</volume>: <fpage>161</fpage>–<lpage>174</lpage>.</citation></ref>
<ref id="bibr42-0333102411435986"><label>42.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>SM</given-names></name><name><surname>Dionne</surname><given-names>RA</given-names></name><name><surname>Brahim</surname><given-names>J</given-names></name><name><surname>Jabir</surname><given-names>F</given-names></name><name><surname>Dubner</surname><given-names>R</given-names></name></person-group>. <article-title>Blockade of peripheral neuronal barrage reduces postoperative pain</article-title>. <source>Pain</source> <year>1997</year>; <volume>70</volume>: <fpage>209</fpage>–<lpage>215</lpage>.</citation></ref>
<ref id="bibr43-0333102411435986"><label>43.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gottschalk</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>DS</given-names></name><name><surname>Jobes</surname><given-names>DR</given-names></name><name><surname>Kennedy</surname><given-names>SK</given-names></name><name><surname>Lally</surname><given-names>SE</given-names></name><name><surname>Noble</surname><given-names>VE</given-names></name><etal/></person-group>. <article-title>Preemptive epidural analgesia and recovery from radical prostatectomy: a randomized controlled trial</article-title>. <source>JAMA</source> <year>1998</year>; <volume>279</volume>: <fpage>1076</fpage>–<lpage>1082</lpage>.</citation></ref>
<ref id="bibr44-0333102411435986"><label>44.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tverskoy</surname><given-names>M</given-names></name><name><surname>Oz</surname><given-names>Y</given-names></name><name><surname>Isakson</surname><given-names>A</given-names></name><name><surname>Finger</surname><given-names>J</given-names></name><name><surname>Bradley</surname><given-names>EL</given-names><suffix>Jr</suffix></name><name><surname>Kissin</surname><given-names>I</given-names></name></person-group>. <article-title>Preemptive effect of fentanyl and ketamine on postoperative pain and wound hyperalgesia</article-title>. <source>Anesth Analg</source> <year>1994</year>; <volume>78</volume>: <fpage>205</fpage>–<lpage>209</lpage>.</citation></ref>
<ref id="bibr45-0333102411435986"><label>45.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Puig</surname><given-names>S</given-names></name><name><surname>Sorkin</surname><given-names>LS</given-names></name></person-group>. <article-title>Formalin-evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase-2 activity</article-title>. <source>Pain</source> <year>1996</year>; <volume>64</volume>: <fpage>345</fpage>–<lpage>355</lpage>.</citation></ref>
<ref id="bibr46-0333102411435986"><label>46.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dickenson</surname><given-names>AH</given-names></name><name><surname>Sullivan</surname><given-names>AF</given-names></name></person-group>. <article-title>Peripheral origins and central modulation of subcutaneous formalin-induced activity of rat dorsal horn neurones</article-title>. <source>Neurosci Lett</source> <year>1987</year>; <volume>83</volume>: <fpage>207</fpage>–<lpage>211</lpage>.</citation></ref>
<ref id="bibr47-0333102411435986"><label>47.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raboisson</surname><given-names>P</given-names></name><name><surname>Dallel</surname><given-names>R</given-names></name><name><surname>Clavelou</surname><given-names>P</given-names></name><name><surname>Sessle</surname><given-names>BJ</given-names></name><name><surname>Woda</surname><given-names>A</given-names></name></person-group>. <article-title>Effects of subcutaneous formalin on the activity of trigeminal brain stem nociceptive neurones in the rat</article-title>. <source>J Neurophysiol</source> <year>1995</year>; <volume>73</volume>: <fpage>496</fpage>–<lpage>505</lpage>.</citation></ref>
<ref id="bibr48-0333102411435986"><label>48.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carlton</surname><given-names>SM</given-names></name><name><surname>Hargett</surname><given-names>GL</given-names></name></person-group>. <article-title>Treatment with the NMDA antagonist memantine attenuates nociceptive responses to mechanical stimulation in neuropathic rats</article-title>. <source>Neurosci Lett</source> <year>1995</year>; <volume>198</volume>: <fpage>115</fpage>–<lpage>118</lpage>.</citation></ref>
<ref id="bibr49-0333102411435986"><label>49.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coderre</surname><given-names>TJ</given-names></name><name><surname>Melzack</surname><given-names>R</given-names></name></person-group>. <article-title>The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury</article-title>. <source>J Neurosci</source> <year>1992</year>; <volume>12</volume>: <fpage>3665</fpage>–<lpage>3670</lpage>.</citation></ref>
<ref id="bibr50-0333102411435986"><label>50.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>CG</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Quack</surname><given-names>G</given-names></name></person-group>. <article-title>Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist–a review of preclinical data</article-title>. <source>Neuropharmacology</source> <year>1999</year>; <volume>38</volume>: <fpage>735</fpage>–<lpage>767</lpage>.</citation></ref>
<ref id="bibr51-0333102411435986"><label>51.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hargreaves</surname><given-names>EL</given-names></name><name><surname>Cain</surname><given-names>DP</given-names></name></person-group>. <article-title>Hyperactivity, hyper-reactivity, and sensorimotor deficits induced by low doses of the N-methyl-D-aspartate non-competitive channel blocker MK801</article-title>. <source>Behav Brain Res</source> <year>1992</year>; <volume>47</volume>: <fpage>23</fpage>–<lpage>33</lpage>.</citation></ref>
<ref id="bibr52-0333102411435986"><label>52.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woolf</surname><given-names>CJ</given-names></name></person-group>. <article-title>Windup and central sensitization are not equivalent</article-title>. <source>Pain</source> <year>1996</year>; <volume>66</volume>: <fpage>105</fpage>–<lpage>108</lpage>.</citation></ref>
<ref id="bibr53-0333102411435986"><label>53.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>SN</given-names></name><name><surname>Lodge</surname><given-names>D</given-names></name></person-group>. <article-title>Evidence for involvement of N-methylaspartate receptors in 'wind-up' of class 2 neurones in the dorsal horn of the rat</article-title>. <source>Brain Res</source> <year>1987</year>; <volume>424</volume>: <fpage>402</fpage>–<lpage>406</lpage>.</citation></ref>
<ref id="bibr54-0333102411435986"><label>54.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>SP</given-names></name><name><surname>Perl</surname><given-names>ER</given-names></name></person-group>. <article-title>Comparison of primary afferent and glutamate excitation of neurons in the mammalian spinal dorsal horn</article-title>. <source>J Neurosci</source> <year>1988</year>; <volume>8</volume>: <fpage>2062</fpage>–<lpage>2073</lpage>.</citation></ref>
<ref id="bibr55-0333102411435986"><label>55.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dickenson</surname><given-names>AH</given-names></name><name><surname>Sullivan</surname><given-names>AF</given-names></name></person-group>. <article-title>Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation</article-title>. <source>Neuropharmacology</source> <year>1987</year>; <volume>26</volume>: <fpage>1235</fpage>–<lpage>1238</lpage>.</citation></ref>
<ref id="bibr56-0333102411435986"><label>56.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Monyer</surname><given-names>H</given-names></name><name><surname>Burnashev</surname><given-names>N</given-names></name><name><surname>Laurie</surname><given-names>DJ</given-names></name><name><surname>Sakmann</surname><given-names>B</given-names></name><name><surname>Seeburg</surname><given-names>PH</given-names></name></person-group>. <article-title>Developmental and regional expression in the rat brain and functional properties of four NMDA receptors</article-title>. <source>Neuron</source> <year>1994</year>; <volume>12</volume>: <fpage>529</fpage>–<lpage>540</lpage>.</citation></ref>
<ref id="bibr57-0333102411435986"><label>57.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boyce</surname><given-names>S</given-names></name><name><surname>Wyatt</surname><given-names>A</given-names></name><name><surname>Webb</surname><given-names>JK</given-names></name><name><surname>O'Donnell</surname><given-names>R</given-names></name><name><surname>Mason</surname><given-names>G</given-names></name><name><surname>Rigby</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn</article-title>. <source>Neuropharmacology</source> <year>1999</year>; <volume>38</volume>: <fpage>611</fpage>–<lpage>623</lpage>.</citation></ref>
<ref id="bibr58-0333102411435986"><label>58.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>G</given-names></name><name><surname>Kocsis</surname><given-names>P</given-names></name><name><surname>Tarnawa</surname><given-names>I</given-names></name><name><surname>Horvath</surname><given-names>C</given-names></name><name><surname>Szombathelyi</surname><given-names>Z</given-names></name><name><surname>Farkas</surname><given-names>S</given-names></name></person-group>. <article-title>NR2B containing NMDA receptor dependent windup of single spinal neurons</article-title>. <source>Neuropharmacology</source> <year>2004</year>; <volume>46</volume>: <fpage>23</fpage>–<lpage>30</lpage>.</citation></ref>
<ref id="bibr59-0333102411435986"><label>59.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chizh</surname><given-names>BA</given-names></name><name><surname>Headley</surname><given-names>PM</given-names></name><name><surname>Tzschentke</surname><given-names>TM</given-names></name></person-group>. <article-title>NMDA receptor antagonists as analgesics: focus on the NR2B subtype</article-title>. <source>Trends Pharmacol Sci</source> <year>2001</year>; <volume>22</volume>: <fpage>636</fpage>–<lpage>642</lpage>.</citation></ref>
<ref id="bibr60-0333102411435986"><label>60.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhuo</surname><given-names>M</given-names></name></person-group>. <article-title>Glutamate receptors and persistent pain: targeting forebrain NR2B subunits</article-title>. <source>Drug Discov Today</source> <year>2002</year>; <volume>7</volume>: <fpage>259</fpage>–<lpage>267</lpage>.</citation></ref>
<ref id="bibr61-0333102411435986"><label>61.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>PH</given-names></name><name><surname>Yang</surname><given-names>LC</given-names></name><name><surname>Shih</surname><given-names>HC</given-names></name><name><surname>Lan</surname><given-names>KC</given-names></name><name><surname>Cheng</surname><given-names>JT</given-names></name></person-group>. <article-title>Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat</article-title>. <source>Gene Ther</source> <year>2005</year>; <volume>12</volume>: <fpage>59</fpage>–<lpage>66</lpage>.</citation></ref>
<ref id="bibr62-0333102411435986"><label>62.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gurwitz</surname><given-names>D</given-names></name><name><surname>Weizman</surname><given-names>A</given-names></name></person-group>. <article-title>The NR2B subunit of glutamate receptors as a potential target for relieving chronic pain: prospects and concerns</article-title>. <source>Drug Discov Today</source> <year>2002</year>; <volume>7</volume>: <fpage>403</fpage>–<lpage>406</lpage>.</citation></ref>
<ref id="bibr63-0333102411435986"><label>63.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lipton</surname><given-names>SA</given-names></name></person-group>. <article-title>Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation</article-title>. <source>Curr Drug Targets</source> <year>2007</year>; <volume>8</volume>: <fpage>621</fpage>–<lpage>632</lpage>.</citation></ref>
<ref id="bibr64-0333102411435986"><label>64.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schneiderman</surname><given-names>JH</given-names></name></person-group>. <article-title>Topiramate: pharmacokinetics and pharmacodynamics</article-title>. <source>Can J Neurol Sci</source> <year>1998</year>; <volume>25</volume>: <fpage>S3</fpage>–<lpage>S5</lpage>.</citation></ref>
</ref-list>
</back>
</article>